Clinical trials: Antibody
Diffuse Large B-Cell Lymphoma, Follicular Lymphoma
Combination Antibody Therapy for Relapsed Lymphoma and Chronic Lymphocytic Leukemia
This study will evaluate the safety and effectiveness of a combination of two antibodies, apolizumab and rituximab (Rituxan ), in treating B-cell lymphomas and chronic lymphocytic leukemia.
- Conditions
- Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma
- Trial name
- NCT00022971
- Testing
- Apolizumab, Rituximab
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- National Cancer Institute (NCI)
Malignant Lymphoma
Safety, Tolerability, Pharmacokinetics & Pharmacodynamics of Toripalimab for Patients With Recurrent Malignant Lymphoma
The primary objective is to assess the safety and tolerability of JS-001 in subjects with recurrent malignant lymphoma, and to evaluate its preliminary efficacy.
- Trial name
- NCT03316144
- Testing
- Toripalimab
- Where
- China
- Volunteers
- 13 people
- Sponsor
- Shanghai Junshi Bioscience Co., Ltd.
Thyroid Neoplasms
P53 in Differentiated Thyroid Cancer
In clinical practise patients with negative radioiodine scan with positive tyhroglobulin is considered as radioiodine resistant or in another words in the process of dedifferentiation.
- Trial name
- NCT01954134
- Where
- Turkey (Türkiye)
- Volunteers
- 199 people
- Sponsor
- Cumhuriyet University
Metastatic Gastric Cancer, Locally Advanced Gastric Adenocarcinoma
Conversion Effects of PD-1 Antibody Camrelizumab Combined With Nab-POF Regimen Chemotherpy in Patients With Initially Unresectable Locally Advanced or Limited Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma：FDZL-GC001 Trial
This study is to evaluate the efficacy and safety of domestic programmed death 1（ PD-1） antibody (Camrelizumab for injection) combined with fluorouracil plus leucovorin, oxaliplatin, and albumin bound paclitaxel (Nab-POF) regimen…
- Conditions
- Metastatic Gastric Cancer, Locally Advanced Gastric Adenocarcinoma, Gastric Cancer Adenocarcinoma Metastatic
- Trial name
- NCT04510064
- Testing
- Camrelizumab plus mFLOT regimen, R0 surgery
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Fudan University
Liver Transplantation
The Favorable Impact of HBcAb Positive Grafts on Liver Transplantation for HBV-related HCC
The utilization of marginal grafts may help alleviate the demand mismatch. However, strategies to optimize the use of hepatitis B core antibody (HBcAb) positive grafts still requires further investigation.
- Trial name
- NCT06787534
- Testing
- No Interventions
- Volunteers
- 6,924 people
- Sponsor
- Xiao Xu
Bone Metastases
Efficacy and Safety of MW032 and Xgeva® in Subjects With Bone Metastases From Solid Tumors
A multi-center, randomized, double-blind, parallel controlled Phase III clinical study to evaluate the clinical efficacy and safety of MW032 and Xgeva® in patients with bone metastases from solid tumors.
- Trial name
- NCT04812509
- Testing
- MW032, Xgeva
- Where
- China
- Volunteers
- 708 people
- Sponsor
- Mabwell (Shanghai) Bioscience Co., Ltd.
Extensive-stage Small-cell Lung Cancer
Ifinatamab Deruxtecan (I-DXd) in Subjects With Pretreated Extensive-Stage Small Cell Lung Cancer (ES-SCLC)
This 2-part study intends to define the recommended Phase 2 dose of ifinatamab deruxtecan (I-DXd) based on the efficacy, safety, and pharmacokinetics (PK) results observed in participants with Extensive-stage Small Cell Lung…
- Trial name
- IDeate-Lung01 (NCT05280470)
- Testing
- Ifinatamab Deruxtecan (I-DXd)
- Where
- 58 sites in United States, China and 6 more
- Volunteers
- 187 people
- Sponsor
- Daiichi Sankyo
AL Amyloidosis
Allo SCT in Amyloidosis Non-interventional Study
Light-chain (AL-) amyloidosis is a very rare monoclonal plasma cell disorder with poor prognosis. Rarity of disease has precluded performance of randomized controlled trials comparing various possible treatment modalities.
- Trial name
- NCT02257905
- Where
- 4 sites in France, Germany and 1 more
- Volunteers
- 14 people
- Sponsor
- European Society for Blood and Marrow Transplantation
Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell
A Study of JNJ-80948543, a T-cell Redirecting CD79b x CD20 x CD3 Trispecific Antibody, in Participants With Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)
The purpose of this study is to characterize safety and to determine the putative recommended Phase 2 dose(s) (RP2D[s]), optimal dosing schedule(s) and route(s) of administration of JNJ-80948543 in Part A (Dose Escalation) and to…
- Trial name
- NCT05424822
- Testing
- JNJ-80948543
- Where
- 29 sites in United States, Australia and 6 more
- Volunteers
- 167 people
- Sponsor
- Janssen Research & Development, LLC
Anterior Uveitis
Exploratory Study on Topical ESBA105 in Acute Anterior Uveitis
The purpose of this study is to determine whether ESBA105, a topically applied TNF-alpha inhibitor, is safe and clinically active when applied to the eye of patients suffering from acute anterior uveitis
- Trial name
- NCT00823173
- Testing
- ESBA105
- Where
- 3 sites in Germany
- Volunteers
- 9 people
- Sponsor
- ESBATech AG
Locally Advanced Rectal Cancer With Liver Metastases
SCRT(Short Course Radiotherapy) Combined With CAPOX Plus QL1706 for Rectal Cancer Liver Metastases
To enhance the treatment efficacy of rectal cancer liver metastasis through a multidisciplinary approach of radiotherapy, immunotherapy, and chemotherapy, and to provide a new direction for the combination treatment strategy.
- Trial name
- NCT06787183
- Testing
- Short course radiotherapy, Capecitabine, Oxaliplatin
- Where
- 2 sites in China
- Volunteers
- 42 people
- Sponsor
- Fujian Cancer Hospital
Immune Thrombocytopenia (ITP)
IgIV Plus Prednisone vs High-dose Dexamethasone for ITP
ITP patients with low platelet count and active bleeding symptoms are at risk of life-threatening bleeding and therefore require a treatment with a rapid effect, reliable, and sustained.
- Trial name
- IVIORDEX (NCT04968899)
- Testing
- Neofordex®, Intravenous immunoglobulins
- Where
- France
- Volunteers
- 272 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Primary Amyloidosis of Light Chain Type
Epigallocatechingallate (EGCG) in Cardiac AL Amyloidosis
In a proportion of patients with AL amyloidosis there is no improvement of cardiac function despite hematologic response to treatment.
- Trial name
- EpiCardiAL (NCT01511263)
- Testing
- Diuretics (plus antiarrhythmic drugs, i.e. amiodarone, in case of complex ventricular arrhithmias), Diuretics (plus antiarrhythmic drugs, i.e. amiodarone, in case of complex ventricular arrhythmias) plus EGCG
- Where
- Italy
- Volunteers
- 86 people
- Sponsor
- Fondazione IRCCS Policlinico San Matteo di Pavia
Non-Small Cell Lung Cancer, Chemotherapy
Randomized Trial of Glutathione With Anti-PD-1 and Chemotherapy in Advanced NSCLC
Chemotherapeutic agents exert significant immunomodulatory effects by influencing tumor-infiltrating immune cells. However, the sequence and combination of chemotherapy regimens differentially modulate immune cell dynamics…
- Conditions
- Non-Small Cell Lung Cancer, Chemotherapy, PD1 Antibody, Glutathione
- Trial name
- NCT06896422
- Testing
- Glutathione, PD1 Inhibitor, Chemotherapy
- Where
- China
- Volunteers
- 80 people
- Sponsor
- The First Affiliated Hospital of Zhengzhou University
Primary Immunodeficiency
Study of ProMetic BioTherapeutics Immune Globulin Intravenous (Human) 10%
Phase 3 multicenter, open-label study of safety, tolerability, efficacy, and pharmacokinetics (PK) of ProMetic's Immune Globulin Intravenous (Human) 10%, the investigational medicinal product [IMP]), in Adults and Children with…
- Trial name
- NCT02269163
- Testing
- Immune Globulin Intravenous, Prometic's Immune Globulin Intravenous 10%
- Where
- 13 sites in United States
- Volunteers
- 82 people
- Sponsor
- Prometic Biotherapeutics, Inc.
Kawasaki Disease
Study of Efficacy and Safety of Canakinumab in Pediatric Patients With Kawasaki Disease
The purpose of this trial is to evaluate whether, in Intravenous Immunoglobulin-naïve or refractory patients diagnosed with active Kawasaki disease, administration of canakinumab controls fever and acute phase reactants.
- Trial name
- NCT02980263
- Testing
- Canakinumab
- Sponsor
- Novartis Pharmaceuticals
Solid Tumor
Phase 1 Study of HLX10, a Monoclonal Antibody Targeting Programmed Death-1 (PD-1) in Patients With Advanced Solid Tumors
The purpose of this study is to determine the maximum tolerated dose (MTD) and recommended Phase 2 dose (RP2D) of humanized anti-PD-1 monoclonal antibody, HLX10, in patients with advanced or metastatic tumors refractory to…
- Trial name
- NCT03468751
- Testing
- HLX10
- Where
- Taiwan
- Volunteers
- 30 people
- Sponsor
- Henlix, Inc
IgA Nephropathy (IgAN), Immunoglobulin A Nephropathy (IgAN)
Mechanistic Evaluation of Atrasentan in Patients With IgA Nephropathy (IgAN)
This multicenter, single-arm, open-label Phase 4 pilot study evaluates the effects of atrasentan added to optimized supportive care on kidney structure and function in adults with biopsy-confirmed IgA nephropathy.
- Trial name
- A-MECH (NCT07820995)
- Testing
- atrasentan
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of Illinois Chicago
Non Small Cell Lung Cancer
Pembrolizumab in Combination With Radiotherapy in Locally Advanced Non-Small Cell Lung Cancer (NSCLC)
Lung cancer is the leading cause of cancer mortality worldwide and in the U.K alone; there are 38,000 new cases of non-small cell lung cancer (NSCLC) a year.
- Trial name
- PARIS (NCT03245177)
- Testing
- Pembrolizumab, Radiotherapy
- Sponsor
- Prof Corinne Faivre-Finn
Recurrent Glioblastoma Multiforme
Safety & Radiation Distribution Study of Cotara® in Patients With Recurrent Glioblastoma Multiforme
RATIONALE: Cotara® is an experimental new treatment that links a radioactive isotope (iodine 131) to a targeted monoclonal antibody.
- Trial name
- NCT00509301
- Testing
- 131-I-chTNT-1/B MAB
- Where
- 4 sites in United States
- Volunteers
- 12 people
- Sponsor
- Peregrine Pharmaceuticals
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.